Zydus gets USFDA nod for injectable drug with 180-day exclusivity

Zydus gets USFDA nod for injectable drug with 180-day exclusivity. Zydus Lifesciences announced final approval from the USFDA for Indocyanine Green for Injection, granting it 180-day Competitive Generic Therapy (CGT) exclusivity. This approval allows Zydus to launch the product ahead of competitors, potentially capturing early market share. The exclusivity period is expected to provide a revenue boost in the near term.

📊 STOCKS: $ZYDUSLIFE | 🏢 SECTOR: Pharma | #MEDIUMIMPACT #USFDA